19-Hydroxy-PGE2 | 55123-68-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 19-Hydroxy-PGE2
• 英文别名: (Z)-7-[(1R,2R,3R)-2-[(E,3S,7R)-3,7-dihydroxyoct-1-enyl]-3-hydroxy-5-oxocyclopentyl]hept-5-enoic acid
• CAS: 55123-68-7
• 化学式: C₂₀H₃₂O₆
• 分子量: 368.5
• InChiKey: WTJYDBMHYPQFNJ-ZUVVJKHESA-N

物化性质

• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  26
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  115
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• SUBSTITUTED CYCLOPENTANES HAVING PROSTAGLANDIN ACTIVITY
  申请人：Burk Robert M.

  公开号：US20090143461A1

  公开（公告）日：2009-06-04

  Disclosed herein are compounds having a formula: Therapeutic methods, medicaments, and compositions related thereto are also disclosed.

  本文披露了具有以下化学式的化合物：同时还披露了相关的治疗方法、药物和组合物。
• PROSTAGLANDIN ANALOGS AND USES THEREOF
  申请人：Lifex Biolabs, Inc.

  公开号：US20210139435A1

  公开（公告）日：2021-05-13

  The present invention relates to pharmaceutical composition for the prevention or treatment of a disease, disorder, or condition associated with Nurr1, including, as an active ingredient, a prostaglandin analog or a pharmaceutically acceptable salt thereof, wherein the compound has excellent effects in inducing Nurr1, and thus, can be useful as a pharmaceutical composition for the prevention or treatment of a disease, disorder, or condition associated with Nurr1, in particular, cancer, autoimmune disease such as rheumatoid arthritis, schizophrenia, manic depression and neurodegenerative disease such as Alzheimers disease or Parkinson's disease.

  本发明涉及一种药物组合物，用于预防或治疗与Nurr1相关的疾病、紊乱或状况，其中包括作为活性成分的前列腺素类似物或其药学上可接受的盐，该化合物具有良好的诱导Nurr1的效果，因此，可用作预防或治疗与Nurr1相关的疾病、紊乱或状况的药物组合物，特别是癌症、自身免疫性疾病如类风湿关节炎、精神分裂症、躁郁症以及神经退行性疾病如阿尔茨海默病或帕金森病。
• ERECTILE DYSFUNCTION REMEDIES CONTAINING PROSTAGLANDIN DERIVATIVES AS THE ACTIVE INGREDIENT
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1306087A1

  公开（公告）日：2003-05-02

  Therapeutic agents for erectile dysfunction containing as the active ingredient prostaglandin derivatives of formula (I) (wherein, R1 is ethyl or n-2-propenyl.), esters thereof, nontoxic salts thereof, or cyclodextrin clathrate compounds thereof. The compounds of the formula (I) are useful for the treatment of erectile dysfunction.

  治疗勃起功能障碍的药物，其活性成分为式(I)的前列腺素衍生物（其中 R1 为乙基或 n-2-丙烯基）、其酯类、其无毒盐类或其环糊精凝块化合物。 (其中，R1 为乙基或 n-2-丙烯基）、其酯类、其无毒盐类或其环糊精凝块化合物。 式（I）化合物可用于治疗勃起功能障碍。
• Synergistic combination of an anti-IgE antibody and an EP2 receptor agonist
  申请人：Universitat Autònoma de Barcelona

  公开号：EP2818484A1

  公开（公告）日：2014-12-31

  The present invention relates to synergistic combinations, including immunoconjugates, of an anti-IgE antibody, such as omalizumab, with an EP2 receptor agonist and their use in the prevention or treatment of an IgE-mediated disorder, preferably asthma.

  本发明涉及抗 IgE 抗体（例如奥马珠单抗）与 EP2 受体激动剂的协同组合（包括免疫结合剂），以及它们在预防或治疗 IgE 介导的疾病（最好是哮喘）中的用途。
• PROSTAGLANDIN RECEPTOR AGONISTS FOR USE IN THE TREATMENT OF A CORONAVIRUS INFECTION SUCH AS COVID-19
  申请人：Medetia

  公开号：EP3981410A1

  公开（公告）日：2022-04-13

  The present invention relates to prostaglandin receptor agonists, such as EP2 and/or EP4 agonists, preferably EP2 agonists, for treating a disease caused by a coronavirus infection, such as COVID-19, in a subject in need thereof, especially in a subject at risk to develop a severe form and/or a complication of said disease.

  本发明涉及前列腺素受体激动剂，如EP2和/或EP4激动剂，优选EP2激动剂，用于治疗由冠状病毒感染（如COVID-19）引起的疾病，适用于有需要的受试者，特别是有可能患上上述疾病的严重形式和/或并发症的受试者。